Cargando…

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence

Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publicatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilson, Erica, Scott, Daniel A., Schmoele-Thoma, Beate, Watson, Wendy, Moran, Mary M., Isturiz, Raul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746253/ https://www.ncbi.nlm.nih.gov/pubmed/32530360 http://dx.doi.org/10.1080/21645515.2020.1735224

Ejemplares similares

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
por: Vietri, Jeffrey, et al.
Publicado: (2019)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
por: Juergens, Christine, et al.
Publicado: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

1442. Pneumonia Hospitalizations Averted With 13-Valent Pneumococcal Conjugate Vaccination of Adults Aged 18–64 Years With Diabetes in the United States
por: Suaya, Jose, et al.
Publicado: (2018)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial
por: Shiramoto, Masanari, et al.
Publicado: (2014)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults
por: Isturiz, Raul, et al.
Publicado: (2015)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
por: Thompson, Allison R., et al.
Publicado: (2018)

Sequential Administration of PCV13 Followed by PPSV23 Results in a More Robust Immune Response in PPSV23-Naïve Adults Age 60–64 Years
por: Chilson, Erica, et al.
Publicado: (2017)

Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
por: Farkouh, Raymond A., et al.
Publicado: (2015)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
por: McLaughlin, John M., et al.
Publicado: (2019)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
por: Wasserman, Matt, et al.
Publicado: (2021)

1438. Uptake of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Adults Aged 19–64 Years: A Kaplan–Meier Approach
por: Vietri, Jeffrey, et al.
Publicado: (2018)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
por: McLaughlin, John, et al.
Publicado: (2017)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
por: Vojicic, Jelena, et al.
Publicado: (2018)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

1446. Correlation Between Adult Invasive and Noninvasive Streptococcus pneumoniae Disease in 13-Valent Pneumococcal Conjugate Vaccine Serotypes in the United States
por: Suaya, Jose A, et al.
Publicado: (2018)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
por: Bennett, Nancy M., et al.
Publicado: (2013)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants
por: Pomat, William S, et al.
Publicado: (2019)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data
por: Feng, Shuo, et al.
Publicado: (2023)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ddn4r62vfuaikqah7ut77geivj